|
|
Predictive Factors for Relapse in Localized Triple-Negative Breast Cancer
|
Abstract:
Introduction: Triple-negative breast cancer (TNBC) has a poor prognosis with a high relapse rate. This study aims to identify predictors of relapse in a Moroccan cohort. Methods: A retrospective study including 130 patients treated between 2016 and 2021. Analysis of clinicopathological characteristics and biological markers (Ki-67, TILs, HER2-low status) was performed. Results: The overall relapse rate was 21.5%. Factors significantly associated with an increased risk were: lymph node involvement (39% vs 7% for N0, p < 0.001), Ki-67 > 80% (50% relapse rate, p < 0.001), and absence of pCR (28% vs 0%, p < 0.001). High TILs (≥50%) were protective (12.9% relapse vs 26.8% for low TILs, p = 0.03). Discussion: Our results confirm data from the literature regarding the prognostic role of nodal status, Ki-67, and pCR. The predictive value of TILs, particularly moderate levels (11% - 49%), warrants further exploration. Conclusion: This study identifies high-risk subgroups justifying a personalized therapeutic approach, while highlighting the potential of immunological markers as predictive factors.
| [1] | Bianchini, G., Balko, J.M., Mayer, I.A., Sanders, M.E. and Gianni, L. (2016) Triple-negative Breast Cancer: Challenges and Opportunities of a Heterogeneous Disease. Nature Reviews Clinical Oncology, 13, 674-690. https://doi.org/10.1038/nrclinonc.2016.66 |
| [2] | Foulkes, W.D., Smith, I.E. and Reis-Filho, J.S. (2010) Triple-Negative Breast Cancer. New England Journal of Medicine, 363, 1938-1948. https://doi.org/10.1056/nejmra1001389 |
| [3] | Dent, R., Trudeau, M., Pritchard, K.I., Hanna, W.M., Kahn, H.K., Sawka, C.A., et al. (2007) Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clinical Cancer Research, 13, 4429-4434. https://doi.org/10.1158/1078-0432.ccr-06-3045 |
| [4] | Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., et al. (2020) Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 382, 810-821. https://doi.org/10.1056/nejmoa1910549 |
| [5] | Cortazar, P., Zhang, L. Untch, M. et al. (2014) Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer. The Lancet, 384, 164-172. |
| [6] | Salgado, R., Denkert, C., Demaria, S., et al. (2015) The Evaluation of Tumor-Infiltrating Lymphocytes in Breast Cancer. Annals of Oncology, 26, 259-271. |
| [7] | Liedtke, C., Mazouni, C., Hess, K.R., et al. (2008) Response to Neoadjuvant Therapy and Long-Term Survival in TNBC. Journal of Clinical Oncology, 26, 1275-1281. |
| [8] | Modi, S., Jacot, W., Yamashita, T., et al. (2022) Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer. The New England Journal of Medicine, 387, 9-20. |
| [9] | CNGOF (2012) Tumeurs triple négatives du sein: Facteurs pronostiques et prédictifs. |
| [10] | Del Paggio, J.C., Fernandes, R., Shettigar, A., et al. (2024) Tumor-Infiltrating Lymphocytes and Survival in Early-Stage Triple-Negative Breast Cancer. JAMA, 331, 654-664. |
| [11] | Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U. and Harbeck, N. (2017) Ki-67 as a Prognostic Marker in Triple-Negative Breast Cancer: Results from the GEICAM/9906 Trial. Breast Cancer Research and Treatment, 165, 119-128. |
| [12] | André, F. and Zielinski, C.C. (2012) Optimal Strategies for the Treatment of Metastatic Triple-Negative Breast Cancer with Currently Approved Agents. Annals of Oncology, 23, vi46-vi51. https://doi.org/10.1093/annonc/mds195 |
| [13] | Tarantino, P., Hamilton, E., Tolaney, S.M., et al. (2022) HER2-Low Breast Cancer: Pathological and Clinical Landscape. Journal of Clinical Oncology, 38, 1951-1962. |
| [14] | Benider, A., Harif, M., Karkouri, M., et al. (2018) Cancer du sein au Maroc: Aspects épidémiologiques et tendances. Bulletin du Cancer, 105, 676-682. |
